Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.
Joined July 2015
- Tweets 251
- Following 591
- Followers 368
- Likes 347
Photos and videos
Ian Setliff retweeted
7 Jul 2023
TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells dlvr.it/SrrW3Y
1
1
954
Ian Setliff retweeted
23 Mar 2022
High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science.
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing frontiersin.org/article/10.3…
1
8
27
Ian Setliff retweeted
3 Mar 2022
#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies.
Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified.
Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions
3 Mar 2022
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking go.nature.com/35O9Ali
3
14
48
9 Nov 2021
Great place to do science!
9 Nov 2021
We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies.
Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!
1
1
6
19 Sep 2021
18 Sep 2021
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…
4
Ian Setliff retweeted
18 Sep 2021
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…
2
27
79
Ian Setliff retweeted
12 Apr 2021
More #COVID19 News: Positive results from a Phase 3 trial in recently infected asymptomatic patients demonstrate the ability of our investigational antibody cocktail to reduce progression to symptomatic #COVID19. Learn more: bit.ly/3t6f01H
2
11
26
Ian Setliff retweeted
15 Mar 2021
Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: bit.ly/3rOhtNN CC: @Sanofi
1
6
29
Ian Setliff retweeted
4 Mar 2021
Today, the FDA accepted for review our sBLA for a treatment for children aged 6 to 11 years with moderate-to-severe #asthma. Learn more: bit.ly/3kLkyeH @sanofi
5
21
1 Mar 2021
We're looking for a computational immunologist. Come join us! careers.regeneron.com/6gQLWZ…
1
2
2
Ian Setliff retweeted
27 Feb 2021
We announced new data on our investigational medicine for patients with #cat allergy and mild asthma at #AAAAI21. Learn more: bit.ly/3qWbLc5
6
24
Ian Setliff retweeted
22 Feb 2021
With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: bit.ly/3dyViqs
1
12
43
Ian Setliff retweeted
11 Feb 2021
Today the FDA approved a first-of-its-kind treatment for people with #HoFH, an ultra #rare inherited form of high cholesterol. Read the full announcement: bit.ly/2OvpA2U
5
30
Ian Setliff retweeted
9 Feb 2021
Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: bit.ly/2MPuYgO
3
9
37
24 Nov 2020
Great place to do science!
24 Nov 2020
Pursue your passion for #science in a dynamic and innovative environment. Apply by December 1 to be a part of the Regeneron Postdoctoral Program.
2
Ian Setliff retweeted
22 Nov 2020
The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: bit.ly/3lUkZ6e
24
122
282
Ian Setliff retweeted
28 Oct 2020
Announcing positive data from 524 additional non-hospitalized #COVID19 patients in ongoing P2/3 study of Regeneron’s investigational antibody cocktail: bit.ly/3mw6BRl
9
88
190
Ian Setliff retweeted
14 Oct 2020
#Breaking: The FDA has approved our novel anti-viral #antibody medicine for Zaire ebolavirus in adult and pediatric patients. #Ebola Read the full announcement: bit.ly/3nSzCrR
3
32
106
Ian Setliff retweeted
5 Oct 2020
#SoundOn 📣. It’s impossible to be still, especially when we have the power to transform lives. See how we go from #SciencetoMedicine.
22
30
69